HeartFlow today touted that seven new insurers released positive medical policies supporting coverage for its HeartFlow FFRct analysis following a coronary computed tomography angiogram, expanding coverage to a total of 185 million patients.
Redwood City, Calif.-based HeartFlow’s FFRct technology works by taking the data from a standard CT scan and applying algorithms that result in a color-coded 3D “map” detailing the changes in flow across coronary lesions.
Positive medical policies were issued by Cigna, Florida Blue, Blue Cross and Blue Shield plans of Michigan, North Carolina and Vermont, Highmark Inc and Independence Blue Cross, HeartFlow said.
“These positive coverage decisions reinforce the clinical and economic value of the HeartFlow Analysis in addressing how heart disease is diagnosed and treated. With the growing momentum of coverage, a wealth of scientific evidence, and unparalleled technology, the HeartFlow Analysis is poised to become the standard of care for patients with suspected heart disease,” prez & CEO Dr. John Stevens said in a press release.
The new coverage decisions from commercial payers increase the amount of patients eligible for HeartFlow analysis up to 130 million, while 55 million Medicare beneficiaries are covered due to a recent New Technology APC payment decision from the Centers for Medicare & Medicaid Services.
In December, HeartFlow took a $90 million step toward the $150 million it hoped to raise in a Series E round for the cardiac imaging technology it’s marketing.